Cohance Lifesciences to Invest $10 Million in US Bioconjugation Expansion

Cohance Lifesciences, a premier pharmaceutical company from India, is investing $10 million to improve cGMP bioconjugation capabilities in the United States. 

The investment will further strengthen the company’s position in the biologics and ADC (antibody-drug conjuguate) market, to keep pace with growing global demand for biopharmaceuticals.

The investment is focused on expansion of Cohance's current sites in the US to include new infrastructure for the efficiency to facilitate the growing demand for complex bioconjugates including ADCs to treat diseases like cancer with precision using antibodies with a potent drug.

Also Read: How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants

Cohance's expansion to build cGMP facilities for bioconjugation and ADCs will provide assurance for compliance for facilities built for current Good Manufacturing Practice (cGMP), as it regards regulatory and quality expectations imposed by companies such as the US Food and Drug Administration (FDA).

Cohance's expansion is partly motivated by the rising demand for specialized bioconjugation services as pharmaceutical companies increasingly adopt targeted therapies as a way to address patient needs to drive better outcomes.

 The company's capabilities with respect to chemistry, manufacturing, and controls (CMC) will be utilized to ensure they can deliver high-quality bioconjugates for clinical and commercial use. This expansion is expected to contribute to new jobs in the US, particularly in R&D and manufacturing.

This project is reflective of Cohance's commitment to innovation, and its ambitions to lead the biopharmaceutical sector globally. Cohance is looking to better serve its customers abroad and is keen to do this by building upon its presence in the US, including major biotech and pharmaceutical companies.

 The expansion is slated for completion within the next 18 months, to take advantage of the growing demand for bioconjugation technologies while moving forward with precision medicine.